FINANCIAL STATEMENT

For the Year Ended December 31, 2018

Schachter & DePalma LLC
Certified Public Accountants and Consultants

TABLE OF CONTENTS

December 31, 2018

INDEPENDENT AUDITORS' REPORT

FINANCIAL STATEMENTS:

Statement of Financial Position	EXHIBIT A
Statement of Activities	EXHIBIT B
Statement of Functional Expenses	EXHIBIT C
Statement of Cash Flows	EXHIBIT D

NOTES TO FINANCIAL STATEMENTS

Schachter & DePalma LLC

Certified Public Accountants and Consultants 199 Baldwin Road Suite 200 | Parsippany, NJ 07054 Tel. (973) 299-0775 | Fax (973) 299-0811

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Congenital Adrenal Hyperplasia Research,
Education and Support Foundation, Inc.
Union, New Jersey

Report on the Financial Statements

We have audited the accompanying financial statements of Congenital Adrenal Hyperplasia Research, Education and Support Foundation, Inc. (a nonprofit organization) which comprise the statement of financial position as of December 31, 2018, and the related statements of activities, and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies uses and the reasonableness of the significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Congenital Adrenal Hyperplasia Research, Education and Support Foundation, Inc. as of December 31, 2018, and the changes in its net assets and its cash flows for the for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The statement of functional expense on Schedule C is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Schackter & De Palma LLC

Schachter & DePalma, LLC Parsippany, New Jersey

May 23, 2019

STATEMENT OF FINANCIAL POSITION

December 31, 2018		EXHIBIT A
ASSETS		
Cash Cash - Savings Other investments (CD's) Accounts receivable Prepaid expenses Furniture and fixtures and equipment Security deposit	\$ 23,042 210,214 50,903 9,425 4,044 10,568 2,450	
TOTAL ASSETS	\$ 310,646	
LIABILITIES AND NET ASSETS		
Liabilities: Accounts payable Accrued payroll Payroll taxes payable Deferred Revenue	\$ 519 6,703 3,812 2,775	
Total Liabilities	\$ 13,809	
Net Assets: Net assets with donor restrictions Net assets without donor restrictions	\$ - 296,837	
Total Net Assets	\$ 296,837	
TOTAL LIABILITIES AND NET ASSETS	\$ 310,646	

CONGENITAL ADRENAL HYPERPLASIA RESEARCH, EDUCATION AND SUPPORT FOUNDATION, INC. STATEMENT OF ACTIVITIES

For the Year Ended December 31, 2018

EXHIBIT B

	Without Donor Restrictions Restricted		Total	
Revenues: Contributions Loss on sale of investments Interest and dividends	\$	605,332 (2) 4,164	\$ 38,697 - 	\$ 644,029 (2) 4,164
Total Revenues	\$	609,494	\$ 38,697	\$ 648,191
Expenses: Program Management and general Fundraising Total Expenses	\$	504,510 49,576 46,928 601,014	\$ 38,697 - - 38,697	\$ 543,207 49,576 46,928 639,711
INCREASE IN NET ASSETS	\$	8,480	\$ -	\$ 8,480
Net assets, January 1, 2018		288,357	-	288,357
NET ASSETS, DECEMBER 31, 2018	\$	296,837	\$ -	\$ 296,837

CONGENITAL ADRENAL HYPERPLASIA RESEARCH,
EDUCATION AND SUPPORT FOUNDATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
For the Year Ended December 31, 2018

EXHIBIT C

	Totals	\$ 10,674	39,000	11,393	5,909	2,169	120,752		13,155	8,372	2,692	291	12,803	305,866	24,067	24,261	6,435	199	22.024	7,125	5 451		15.829	649	259	¢ 630 711
Donor	Restricted	ı	38,697	1	1	ı	,	ı	ı	1	ı		ı	ı	ı	ı	ı	1	1	ı	ı		ı	1	Ē	38 607
	Fundraising	4,697					19.320			84	108			18,352	1,444	1,213	56		1,321		327				5	46 928 &
nt	& General	3 1,174 \$		228	1,891	2,169				7,080	1,103	291		24,469	1,925		5,575		1,762	1,354	218				I	49.576
	Services	\$ 4,803 \$	303	11,165	4,018		101,432		13,155	1,207	1,481		12,803	263,045	20,698	23,048	804	199	18,941	5,771	4,906		15,829	649	254	\$ 504 510 \$
	1	Bank and credit card fees	Comprehensive care payments	Consulting	Dues and subscriptions	Depreciation	Event costs	Grants:Education	Grants:Research	Insurance	License and permits	Loss on sale of assets	Miscellaneous	Payroll expense	Payroll taxes	Printing, postage and publications	Professional fees	Professional training and education	Rent and cleaning	Supplies & office expense	Telephone and internet	Travel & Entertainment:	Education	Research	Website maintenance	TOTAL EXPENSES

CONGENITAL ADRENAL HYPERPLASIA RESEARCH, EDUCATION AND SUPPORT FOUNDATION, INC. STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2018

EXHIBIT D

	Research WHI Market		
CASH FLOWS FROM OPERATING ACTIVITIES Change in net assets	\$	9.490	
Onango in het assets	Φ	8,480	
Adjustments to reconcile increase in net assets to			
net cash provided by operating activities:			
Depreciation		2,169	
Accounts receivable		(9,425)	
Prepaid expenses and security deposit		15,582	
Accounts payable and other liabilities		(7,662)	
Deferred revenue		(25,859)	
Loss on sale of fixed assets		291	
Loss on sale of investments		2	
		The National Control of the Control	
Net Cash Used for Operating Activities	\$	(16,422)	
CASH FLOWS FROM INVESTING ACTIVITIES:			
Net Investment in fixed assets	\$	(11,758)	
Proceeds from sale of fixed assets		150	
Proceeds from sale of investments	Participation of the Control of the	3,634	
Net Cash Used for Investing Activities	\$	(7,974)	
NET DECREASE IN CASH	\$	(24,396)	
Cash Balance, January 1, 2018		200 555	
Odon Balance, January 1, 2010		308,555	
CASH BALANCE, DECEMBER 31, 2018	\$	284,159	
- · · · · · · · · · · · · · · · · · · ·	-		

CONGENITAL ADRENAL HYPERPLASIA RESEARCH, EDUCATION AND SUPPORT FOUNDATION, INC. NOTES TO FINANCIAL STATEMENTS

December 31, 2018

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Description of Program

Congenital Adrenal Hyperplasia Research, Education and Support Foundation, Inc. is dedicated to educating the public and physicians about all forms of Congenital Adrenal Hyperplasia, its symptoms, diagnostic protocols, treatment, genetic frequency, the necessity of early intervention and benefits of newborn screening. It is also dedicated to providing support and information to affected individuals and their families.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Organization keeps its excess cash in several institutions as of December 31, 2018. The Organization had no uninsured balances.

Income Taxes

The Foundation is exempt from federal income taxes under the Internal Revenue Code, Section 501 (c) (3); accordingly, no provision is made for state and federal income taxes.

Depreciation

Depreciation is provided on the straight-line method over the useful economic life of the assets as follows:

Furniture, Fixtures, and Equipment

5 to 10 years

Donor-Imposed Restrictions

Net assets are released from donor restriction by incurring expenses satisfying the restricted purposes or by occurrence of the passage of time or other events specified by donors.

Allocation of Joint Costs

The financial statements report certain categories of expenses that are attributable to more than one program or supporting function. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries and wages, payroll taxes and benefits, occupancy costs, telephone, insurance and equipment rentals, which are allocated on the basis of estimates of time and effort.

NOTES TO FINANCIAL STATEMENTS

December 31, 2018

NOTE B - CASH

The financial assets available within one year of the balance sheet date for general expenditures are as follows:

Cash and Cash Equivalents	\$ 233,256
Other Investments	50,903
Accounts receivable	9,425
	\$ 293,584

NOTE C - FIXED ASSETS

Fixed assets are stated at cost net of accumulated depreciation as follows:

Computer Equipment	\$ 10,210
Furniture	15,247
Telephone System	 3,950
	\$ 29,407
Less: Accumulated Depreciation	 (18,839)
	\$ 10,568

The Depreciation expense for the year ended December 31, 2018 was \$2,169.

NOTE D - PREPAID EXPENSES

Prepaid expenses in the amount of 4,044 represent deposits and expenses incurred in 2018 for the Organization's 2019 fund raising event in the amount of 2,895 and prepaid insurance in the amount of 1,149.

NOTE E - COMMITMENTS

Starting August 1, 2015 the Foundation leases its office space at 2414 Morris Avenue, Union, New Jersey on a month to month basis. Payments under this lease are \$1,827 a month.

NOTE F - SUBSEQUENT EVENTS

The subsequent events were evaluated through May 23, 2019, the date which the financial statements were available to be issued.

CONGENITAL ADRENAL HYPERPLASIA RESEARCH, EDUCATION AND SUPPORT FOUNDATION, INC. NOTES TO FINANCIAL STATEMENTS December 31, 2018

NOTE G -ACCOUNTING FOR UNCERTAIN TAX POSITIONS

The Company has evaluated its tax position for uncertainties under the guidelines of ASC Codification #740-10-25, with respect to the financial statements for the year ended December 31, 2018. Based on this evaluation, the Company has determined that the liability created for uncertain tax positions at December 31, 2018 is not material.